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and Postoperative Course? A Pilot Study
Alessia Callegari, MD1,2 , Martin Christmann, MD1,2,
Manuela Albisetti, MD, PROF2,3, Oliver Kretschmar, MD, PROF1,2,
and Daniel Quandt, MD1,2
Abstract
This study evaluates coagulation profiles of single ventricle (SV) patients in relationship to liver function, hemodynamic variables
and outcome. Twenty-six children with SV anatomy were included. Advanced coagulation profiles, invasive preoperative
hemodynamic parameters and clinical course were retrospectively analyzed. Median (interquartile range) age and weight at the
time of blood sampling was 25.5 (31) months and 10.5 (6.9) kg. Sixteen patients (16/26; 62%) showed decreased antithrombin and/
or protein C (PC) and/or free protein S (PS) function and/or free PS antigen. Two patients showed abnormal activated PC
resistance ratio due to heterozygous factor V Leiden mutation and 1 heterozygous prothrombin G20210A mutation. Group
comparison (abnormal coagulation profile [group 1; n ¼ 16] versus normal coagulation profile [group 2; n ¼ 10]) showed longer
postoperative hospitalization time (p ¼ .04), longer postoperative catecholamine support (p ¼ .01), a higher incidence of
thromboembolic events (p ¼ .04), and chylothoraxes (p ¼ .007) in group 1. In 5 (31%) of 16 group 1 patients, thromboembolic
complications occurred: cerebral stroke (n¼ 1), intestinal ischemia (n¼ 2), thrombus formation in inferior caval vein (n¼ 1), and
pulmonary vein (n ¼ 1). Abnormalities in coagulation parameters are common in SV patients. Coagulation abnormalities con-
stitute a preoperative risk factor and affect postoperative course.
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Introduction
The Fontan palliation for patients with single ventricle (SV)
anatomies was developed in the 1970s.1 The introduction of
appropriate surgical techniques2 led to a significant improve-
ment in the survival of these patients.3 Nowadays, a total
(extracardiac) cavopulmonary connection is created in most
functional univentricular hearts (UVH), where this is felt to
be the only option to separate the systemic and pulmonary
circulation.4 However, this palliation has intrinsic limitations5
and the management of long-term complications is still a major
topic in the care of these patients.6
Thrombotic and thromboembolic events are a widely recog-
nized complication with an estimated prevalence ranging from
7% to 33%,7 especially during the postoperative management
of these patients. The associated mortality can be as high as
25% and a pathologic coagulation profile influences the
functional state of Fontan patients.7 Because of the complexity
of the coagulation system and a large number of candidate risk
factors, assessing the individual patients’ risk is difficult and
the management of the anticoagulation therapy in these
patients is still controversial. Therefore, it seems important to
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find clinically useful markers to identify children at increased
risk for thrombotic events.
Several reports8-19 have shown a higher prevalence of coagu-
lation factor abnormalities (eg, altered concentrations of protein-
C [PC], protein-S [PS], antithrombin [AT], factors II, V, VII,
VIII, and X) in this patient population, which may have an
important influence on thrombotic events during clinical course.
The coagulation imbalance precedes Norwood stage III pallia-
tion.8,10,11 Therefore, the alterations do not seem to be a direct
consequence of the anatomic and physiologic changes originat-
ing from the Fontan circulation. Hepatic abnormalities resulting
from chronic systemic venous hypertension8,9,13,14,19 and protein
losing enteropathy (PLE)7,20 have been proposed as a plausible
cause for abnormal liver protein synthesis. The role of physio-
logic derangements and endothelial abnormalities originating
from chronic cyanosis,12 low cardiac output, or perhaps even
genetic predisposition21,22 have also been hypothesized.
The relatively high prevalence of thrombotic and throm-
boembolic complications advocates for a better understanding
of the specific impact of the hemodynamic status on the coa-
gulation parameters as well as of the influence of an abnormal
coagulation profile on postoperative course. Therefore, this
analysis aims for a description of some coagulation parameters
in a heterogenous group of SV patients throughout staged pal-
liation. Moreover, we set the target of exploring possible rela-
tionships between coagulation parameters and hemodynamic
variables, liver enzymes, and some clinical parameters (imme-
diately after surgery and at 6 months of follow-up).
Methods
This is a retrospective, chart review study including patients at
the University Children’s Hospital Zurich. Between 2016 and
2018, consecutive patients with univentricular cardiac anatomy
undergoing staged Norwood/Fontan palliation (stage I, II or
III), who underwent cardiac catheterization and received an
advanced assessment of their coagulation profile, were
included in this analysis.
At cardiac catheterization, mean pulmonary artery pressure
(mPAP), mean right atrial pressure (mRAP), systemic ventricle
end-diastolic pressure (EDP), pulmonary capillary wedge pres-
sure (PCWP), arterial oxygen saturation (SaO2), mean trans-
pulmonary pressure gradient (mTPG), pulmonary vascular
resistance (Rp, in WU/m2), and ratio of pulmonary-to-
systemic vascular resistance (Rp/Rs) were assessed. During
introduction of anesthesia, a venous blood sample was taken,
and an advanced evaluation of the coagulation profile was
performed. Antithrombin, PC, free PS function, free PS anti-
gen, activated PC resistance (APC resistance), prothrombin
time (PT), activated partial thromboplastin time (aPTT), Quick
test, and fibrinogen were measured. A screening for a hetero-
zygous factor V Leiden mutation and heterozygous prothrom-
bin G20210A mutation was performed. In addition, N-terminal
pro-brain natriuretic peptide (NT-pro-BNP) level, liver func-
tion parameters and complete blood count were analyzed.
Antithrombin activity was evaluated using a factor Xa-
based chromogenic assay, PC activity using a chromogenic
assay, and free PS with a PT-based clotting assay and with the
antigen concentration of the free form (free PS antigen). The
presence of an altered coagulation screening was defined by an
abnormal AT and/or PC and/or free PS and/or free PS antigen
and/or APC resistance and/or the presence of factor V Leiden
and/or heterozygous prothrombin G20210A mutation. The
patients with an altered coagulation screening were defined
as group 1 and those with a normal coagulation screening as
group 2. The reference values for the coagulation parameters
according to age were taken from Toulon et al,23 and for the
other chemical parameters, internationally validated references
were used. As NT-pro-BNP was markedly skewed, a logarith-
mic transformation was performed.
The medical history of patients from birth to 6 months after
sampling was screened to define cardiac anatomy, baseline
characteristics and surgical history. The development of throm-
boembolic events or extensive bleeding during this time period
was analyzed in detail. Other complications (eg, chylothorax,
diaphragmatic paralysis, PLE, and plastic bronchitis) were
classified as present or absent. To characterize the postsurgical
outcome, the need for postoperative cardiac resuscitation
(mechanical or pharmaceutical), need of inhaled nitric oxide
(iNO), as well as the length of hospital stay, mechanical venti-
lation and catecholamine support were assessed. At 6-month
follow-up survival, the presence of complications and echocar-
diography parameters were assessed.
Statistical analysis was performed using SPSS 25 (SPSS Inc,
IBM Company, Chicago, Illinois). Normally distributed data
were presented as mean and standard deviation and data of
other distributions as median and interquartile range. Group
comparison was performed using 2-sample t test or w2 test.
Levene test for equality of variance was used to test for homo-
geneity of variance. The ordinal, nominal and dichotomical
variables were evaluated with contingency tables and com-
pared with w2 tests. The predictability of the continuous vari-
ables was evaluated by means of Pearson correlations. The
significance is defined by values of p < .05. The study was
conducted in accordance with the Declaration of Helsinki (revi-
sion 2013). The local ethical committee approved the study.
Results
Description of Study Participants
In total, 26 patients were included in the analysis. Baseline
characteristics and clinical/surgical outcome of all patients are
summarized in Table 1. Hemodynamic parameters obtained at
cardiac catheterization are listed in Table 2.
Coagulation Profile, Distribution, and Effects
of Coagulation Abnormalities
Complete results of the analysis of the coagulation profiles are
shown in Table 3. A total of 16 (62%) patients showed at least 1
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abnormality (group 1). Nine (34%) patients had an isolated
reduction in PC; 2 (8%) patients reduced PC and AT; 2 (8%)
patients a heterozygous prothrombin G20210A mutation;
1 (4%) patient a factor V Leiden heterozygous mutation;
1 (4%) patient an isolated reduction in free-PS; and 1 (4%)
patient reduced PC, free-PS, and free-PS-antigen. These
Table 1. Baseline Characteristics of Study Population: Patients With at Least 1 Abnormality in Their Coagulation Profile (Group 1) and Patients
With a Normal Coagulation Profile (Group 2).a
Study Population Total, 26 (100) Group 1, 16 (62) Group 2, 10 (38) P Value
Age (months) 25.5 (31.0) 15.6 (43) 27.0 (26) .6
Male (n) 18 (69) 11 (61) 7 (39) .9
Weight (kg) 10.5 (6.0) 8.6 (8.1) 11.1 (6.6) .6
Height (cm) 78 (30.3) 66.0 (32.8) 82.4 (28) .7
LV (n) 17 (65) 10 (59) 6 (41) .7
RV (n) 9 (35) 7 (78) 2 (22) .7
NT-pro-BNP (ng/L) 376 (697) 333 (382) 766 (1408) .1
Normal (n) 7 (27) 3 (43) 4 (57) .2
1-fold >97th percentile (n) 10 (38) 6 (60) 4 (40) .9
2-fold >97th percentile (n) 9 (35) 7 (78) 2 (22) .2
Hemoglobin (mg/dL) 145+ 23.8 142+ 23 151+ 24 .4
aPTT (seconds) 33.6+ 8.4 36+ 9.8 30+ 3.6 .04
Tc (G/L) 314.0+ 137 349+ 151 257+ 93 .06
Fibrinogen (g/L) 2.4 + 0.6 2.4+ 0.75 2.5+ 0.3 .5
Aspartate transaminase (IU/L) 30.6+ 15 20.5+ 19.6 19.4+ 8.6 .8
>97th percentile (n) 2 (8) 2 (100) 0 (0) .3
Stage of palliation
Stage I (n) 10 (38) 7 (70) 3 (30) .2
Stage II (n) 13 (50) 6 (46) 7 (54) .2
Stage III (n) 3 (12) 3 (100) 0 (0) .2
Outcome
Decease (y/n) 3 (12) 2 (67) 1 (33) .8
iNO (y/n) 5 (19) 4 (80) 1 (20) .5
Resuscitation (y/n) 4 (16) 1 (25) 3 (75) .5
Mechanical ventilation (days) 3.3 + 5.7 4.85+ 7 1.1+ 0.3 .08
Length of hospitalization (days) 18.7+ 8.4 21.3+ 9.5 14.8+ 4.5 .04
Postoperative catecholamine support (days) 2.6 + 2.2 3.5+ 2.5 1.3+ 0.7 .01
Complications
Extensive bleeding (y/n) 2 (8) 2 (100) 0 (0) .2
Thrombosisb (y/n) 5 (19) 5 (100) 0 (0) .05
Plastic bronchitis (y/n) 1 (4) 1 (100) 0 (0) .4
PLE (y/n) 2 (8) 1 (50) 1 (50) .3
Chylothorax (y/n) 8 (31) 8 (100) 0 (0) .007
Abbreviations: aPTT, activated partial thromboplastin time; iNO, inhaled nitric oxide; LV, left ventricle; n, sample number; NT-pro-BNP, N-terminal pro-brain
natriuretic peptide; PLE, protein losing enteropathy; RV, right ventricle; Tc, Thrombocytes; y, yes.
aData presented as mean+ SD/median (interquartile range)/n (%). Group comparison was performed using 2-sample t test or w2 test (significance level P < .05).
bOf systemic-pulmonary artery shunts during stage I palliation, intestinal ischemia or stroke; Percentile of reference values according to age and sex.
Table 2. Illustration of Hemodynamic Variables at the Time of Cardiac Catheterization of Study Population.a
Variables Total, 26 (100) Group 1, 16 (62) Group 2, 10 (38) P Value
mPAP (mmHg) 15.6+ 2.9 16.2+ 3.2 14.7+ 2.3 .2
mRAP (mmHg) 11.8+ 3.3 11.9+ 3.3 11.7+ 3.5 .9
SV-EDP (mmHg) 13.3+ 2.3 13.2+ 2.3 13.4+ 2.4 .9
PCWP (mmHg) 12.0+ 2.9 12.8+ 3.3 10.9+ 1.4 .06
mTPG (mmHg) 3.6+ 2.0 3.4+ 2.3 3.8+ 1.4 .6
SaO2 (%) 83.1+ 14.4 82.5+ 14.8 84.2+ 7.0 .8
Rp (WU/m2) 1.7+ 0.7 1.8+ 0.7 1.4+ 0.4 .09
Rp:Rs 0.12+ 0.06 0.13+ 0.07 0.11+ 0.05 .5
Abbreviations: mPAP, mean pulmonary artery pressure; mRAP, mean right atrial pressure; mTPG, mean transpulmonary pressure gradient; PCWP, pulmonary
capillary wedge pressure; Rp, pulmonary vascular resistance; Rp:Rs, ratio of pulmonary-to-systemic vascular resistance; SV-EDP, single ventricle end-diastolic
pressure; SaO2, arterial oxygen saturation.
aData presented as mean+ standard deviation.
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patients (group 1) compared to patients with a normal coagula-
tion profile (group 2) showed a longer postoperative hospital
stay (21.3 + 9.5 days vs 14.8 + 4.5 days; p ¼ .04), longer
postoperative catecholamine support (3.5+ 2.5 days vs 1.3+
0.7 days; p ¼ .01), a higher incidence of chylothoraxes
(p ¼ .007), and a higher incidence of thromboembolic events
(p¼ .04; Figure 1A and B). Thromboembolic complications or
excessive bleeding occurred in group 1 patients only. Throm-
boembolic complications were documented in 5 (19%) and
excessive bleeding in 2 (8%) patients. Specifically, cerebral
stroke (n ¼ 1), intestinal ischemia (n ¼ 2), thrombus formation
in inferior caval vein (n ¼ 1) and pulmonary vein (n ¼ 1),
thoracic and cerebral bleeding during surgery (n ¼ 1), and
massive bleeding from the endotracheal tube (n ¼ 1) were
described. Finally, aPTT was 36+ 9.8 seconds in group 1 and
30 + 3.6 seconds in group 2 (p ¼ .04).
The 2 groups showed no statistically significant differ-
ences in baseline characteristics (sex, age, cardiac anatomy,
and stage of palliation), other laboratory parameters (liver
function, hemoglobin, platelet count, and NT-pro-BNP), car-
diac catheterization parameters, postsurgical course (regard-
ing length of mechanical ventilation and need of iNO),
fenestration at stage III, development of other long-term com-
plications or echocardiographic assessed cardiac function at
follow-up (see Tables 1 and 2).
Coagulation Profile and Hemodynamic Parameters
Antithrombin correlated positively with SaO2 (p¼ .04; r¼ 0.4;
95% confidence interval [CI]: 0.11-0.78) (Figure 2A) and nega-
tively with Rp (p ¼ .01; r ¼ 0.5; 95% CI: 0.9-0.1; Figure 2B);
patients with a reduced AT (%) had lower SaO2 but higher Rp.
Protein-C correlated negatively with mPAP (p ¼ .02; r ¼ 0.4;
95% CI: 0.8-0.1; Figure 2C) and PCWP (p ¼ .03; r ¼ 0.4; 95%
CI: 0.8-0.3; Figure 2D): reduced PC (%) is associated with
higher mPAP and PCWP. Free PS correlated negatively with
mPAP (p ¼ .01; r ¼ 0.4; 95% CI: 0.8-0.1; Figure 2E) and free-
PS-antigen correlated negatively with mPAP (p ¼ .003; r ¼
0.6; 95% CI: 0.9-0.2; Figure 2F), meaning an increased mPAP
is related to lower free-PS (%) and free-PS-antigen (%). No
correlation was found between the coagulation parameters and
mRAP, EDP, mTPG, and Rp:Rs.
Discussion
In our single-center analysis, a high frequency of abnormalities
in coagulation parameters in patients with UVH physiology
through staged Norwood palliation was found. Moreover, we
identified possible correlations between hemodynamic and
coagulation parameters, while coagulation abnormalities in
addition negatively affected the postoperative course.
According to the Virchow triad, thromboembolism could be
provoked by altered hemodynamic factors (eg, stasis, nonpul-
satile circulation, atrial arrhythmias or sluggish flow), the
presence of abnormal surfaces (eg. prosthetic material, blind
cul-de-sacs, or surgical scars) or clotting factor abnormalities.
All these hemodynamic conditions are present through staged
Table 3. Results of Coagulation Screening in 26 Single Ventricle
Patients and Individual Frequencies of Abnormal Coagulation Para-
meters in the Study Cohort.
Variables 26 (100)
AT (%) 80.7+ 14.0
PC (%) 54.0+ 17.7
Free PS function (%) 79.3+ 24.7
Free PS antigen (%) 87.6+ 18.2
APC resistance (ratio) 2.8 + 0.3
Frequencies of Pathological Results 16 (62)
Reduced PC (%) 9 (34)
Reduced PC and AT (%) 2 (9)
Factor V Leiden mutation (y/n) 2 (8)
Reduced free-PS (%) 1 (4)
Reduced free PS, free PS antigen, and PC (%) 1 (4)
Heterozygous prothrombin G20210A mutation (y/n) 1 (4)
Abbreviations: APC-resistance, activated PC resistance; aPTT, activated partial
thromboplastin time; AT, antithrombin; n, no; PC, protein C; PS, protein S;
y, yes.
aData presented as mean + standard deviation or counts and percentages: n
(%). Comment: Since the normal values are dependent on the age of the
patient, abnormalities are presented as frequencies.
Figure 1. Box plot diagram to illustrate group comparison (normal
coagulation profile¼ group 2 vs abnormal coagulation profile¼ group
1) of postoperative need for catecholamine support (A) and time of
postoperative hospitalization (B) Results expressed as mean. d indi-
cates days.
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Norwood palliation, especially after stage III.13,16,17,24 Since
thromboembolic episodes occur both on the pulmonary venous
and systemic arterial circulation, through all stages of pallia-
tion, the presence of a coagulation disorder seems a reasonable
hypothesis.
The first report on coagulation abnormalities in Fontan
patients was published in 199014 and highlighted an imbalance
between procoagulant and anticoagulant factors leading to a
high thrombotic risk. Later studies showed reduced concentra-
tions of PS, AT and PC after stage II and stage III.13,16 How-
ever, these analyses used adult reference values.25 Odegard
et al have published similar results in children with UVH phy-
siology at all stages of palliation in comparison to age-matched
controls.8-11 Immediately before stage II10 and stage III20
reduced concentrations of PC, PS, factors II, V, VII, IX, and
X, plasminogen, fibrinogen, and AT were described. After
stage III,9 the changes in coagulation parameters were
qualitatively and quantitatively similar, with the important
exception of an increased factor VIII. These findings were
confirmed in 2 prospective longitudinal studies.11,19 In contrast
to these results, Rask et al18 showed a less prothrombotic state
late after Fontan surgery and a normalization of PC has also
been described before.15,16 However, PS activity remained
reduced and increased platelet activation, probably driven by
endothelial damage, was observed.15 In our analysis, we iden-
tified at least 1 highly probable abnormality in coagulation
parameters in 62% of our patient cohort, most frequently
reduced PC.
Deficiencies of AT, PC, or PS, both inherited and/or
acquired, create a prothrombotic state.26 The underlying cause,
as to whether the unbalanced coagulation system abnormalities
are linked to delayed maturation of the coagulation system as a
result of physiological alterations (such as a subclinical form of
PLE, cyanosis, or low cardiac output), remains a speculative
Figure 2. Correlations between coagulation profile parameters and hemodynamic parameters (A-F). Also, see detailed description in the main
manuscript, results section. Results expressed as mean. AT indicates antithrombin; mPAP, mean pulmonary artery pressure; PC, protein C; PS,
protein S; PCWP, pulmonary capillary wedge pressure; Rp, pulmonary vascular resistance; SaO2, arterial oxygen saturation.
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and unlikely hypothesis.8,27 Since PLE is a late complication of
a Fontan circulation, it could be described only in 2 of our
patients (one with an abnormal coagulation); therefore, not
many conclusions could be drawn. Although PC has a short
biological lifetime, a vitamin K deficiency remains an unlikely
explanation of their reduced concentrations. In fact, normal
vitamin K levels, suggesting preserved enteric absorption of
lipid-soluble vitamins, have been described before in this
patient population.14 It could be hypothesized that their deficit
could result from fluctuating and transiently lowered vitamin K
levels or by temporal dysfunction of the vitamin-K-dependent
carboxylase. An acquired deficiency of PC, PS and AT has
been reported in severe liver disease, during disseminated
intravascular coagulation and in the immediate postoperative
period.16 Consequentially, the role of an increased systemic
venous pressure and hepatic congestion (or low perfusion due
to low-cardiac output) in reducing protein synthesis in the liver
has been indicated as a potential driving cause. Severe hepatic
dysfunction was not found in our patients; however, the pres-
ence of elevated transaminases did not appear to be associated
with coagulation abnormalities in our study nor in previous
reports in literature.8,9,13,14,19 This is also supported by the
presence of coagulation abnormalities when inferior caval vein
pressure is not increased.16
These considerations together with the fact that the abnorm-
alities in coagulation factors are present earlier in the course of
staged SV palliation seem to suggest that these abnormalities
do not result from the Fontan physiology only. In accordance
with these considerations is the fact that we only had 3 parti-
cipants in a Fontan circulation in our patients’ group. At stages
I and II, chronic cyanosis and secondary polycythemia (with
associated decreased absolute amounts of clotting factors) may
induce a hypercoagulable state by shifting the endothelial phe-
notype toward a prothrombotic state.12,28,29 In fact, hypoxia
suppresses thrombomodulin in endothelial cells, resulting in a
reduced activation of PC.12 In our analysis, we did not inves-
tigate the complete profile of coagulation parameters; however,
postoperative bleeding was not frequent, pointing to a misba-
lance toward a procoagulatory state. At stage III, the higher
shear stress on the wall of the pulmonary vasculature seems to
alter endothelial function, leading to an increased risk of throm-
bus formation as well as to vasoconstriction.12,17 Finally, an
elevated systemic venous pressure and abnormal flow pattern
may also lead to thrombus formation.17
The reduction of all 3 anticoagulants (PS, PC, and AT)
suggests that the deficiency is acquired rather than hereditary.
A higher prevalence for heterozygous factor V Leiden mutation
or of single-nucleotide polymorphisms of genes encoding pro-
teins involved in coagulation pathways in patients with conge-
nital heart disease or directly after surgery has been reported
before.17,21,22 However, we did not find an increased preva-
lence in our pilot analysis. In fact, only 2 patients showed a
factor V Leiden mutation and 1 a prothrombin G20210A het-
erozygous. Nevertheless, our preliminary results appear to sup-
port the use of these 2 genetic markers in a clinical setting to
identify patients at an increased risk of thromboembolic
complications since 2 out of these 3 patients experienced
severe thromboembolic events direct postoperatively.
To our knowledge, our study is the first to suggest that an
abnormal coagulation profile could be associated with
impaired invasive hemodynamic parameters. Whether the
pathological findings in coagulation parameters negatively
influence hemodynamics or are a result of impaired hemody-
namic parameters, remains unclear. The key question regarding
which role the type of circulation plays in this association also
remains unanswered, especially since we only have a punctual
assessment and could enroll only 3 participants with a Fontan
circulation. However, our results clearly point toward an early
manifestation of coagulation abnormalities. One hypothesis
might be that the altered coagulation relates to a procoagulatory
state, which might be the fundamental for microthrombus for-
mation in the pulmonary vasculature (and/or systemic–pul-
monary shunt). Microthrombus formation might degenerate
into altered (impaired) hemodynamics. This could be sustained
by the positive correlation between AT and SaO2 (described
once before after stage III19), in the sense that lower AT levels
are associated with lower oxygen saturation. The association
between Rp and SaO2 is also in accordance with this theory.
The increased Rp of the patients with a reduced SaO2 could
potentially result from microthrombus formation in the periph-
eral pulmonary vascular bed, which then augments vascular
resistance. Our finding of the relation between a diminished
PC and an increased PCWP would point into the same direction
because we measured the occlusion pressure of the lung capil-
laries that could be influenced by microthrombus formation.
The correlations of reduced PC and PS with increased mPAP
would potentially also support this hypothesis, because these
microthrombus formations could impair the hemorheology and
increase the pressure in the pulmonary arteries. However, these
associations between hemodynamic data and coagulation fac-
tors remain controversial, especially since other studies were
unable to demonstrate any significant correlation with hemo-
dynamics.8-11,16 Nevertheless, a procoagulatory state appears
to have a negative influence on the hemodynamic parameters.
The negative influence of altered coagulation parameters on
the postoperative course seems to be confirmed by a longer post-
operative hospital stay, a longer need of catecholamine support
and a higher incidence of postoperative chylothoraxes in patients
with abnormal coagulation profile in our patients. Theoretically,
this could also be due to an association between impaired ventri-
cular function and impaired hemodynamic parameters prior to
surgery in patients with abnormal coagulation parameters. How-
ever, no association between the NT-pro-BNP values and the
presence of clotting abnormalities could be described.
Finally, the higher prevalence of thromboembolic events and
excessive bleeding that characterized only patients with an
altered coagulation remark the clinical relevance of these results
of our analysis. It is important to report, that (considering the
retrospective design of our study) we could not rule out other
causes (eg. postoperative impaired perfusion) for intestinal
ischemia. However, we only included the 2 cases where the
6 Clinical and Applied Thrombosis/Hemostasis
evaluation of the visceral surgeon considered a thromboembolic
event as very likely due to the intraoperative findings.
Limitations
Our study assessed a heterogeneous patient population (differ-
ent cardiac anatomies, different stages of palliation, etc) and we
did not (yet) examine the full complement of coagulation fac-
tors, especially platelet function tests were not assessed.
Furthermore, since no age-matched controls were enrolled, the
definition of normal/abnormal coagulation profile relies on
previously published norm values and this might constitute a
relevant bias in the interpretation of the results.
Moreover, the family history for coagulation abnormalities
was not taken into account and the analysis was retrospectively
performed, with a small sample size and at a single center.
Especially regarding a comparison of the postoperative course,
although group 1 and group 2 are statistically comparable, the
role of the different surgical interventions (stage II or III) could
not be assessed, which implements limitation to the interpreta-
tion of our results. Finally, without lung biopsies and histological
assessment, the hypothesis of the presence of microthrombus
formation in the pulmonary circulation remains unprovable.
Considering all these limitations, our results are very interesting
hypotheses that support the introduction of a larger, prospective
(potentially multicenter), longitudinal trial also assessing age-
matched controls in the near future.
Conclusion
Abnormalities in coagulation parameters are common in SV
patients. A correlation between hemodynamic and coagulation
parameters can be hypothesized. Coagulation abnormalities
seem to constitute a preoperative risk factor and seem to affect
postoperative course.
Authors’ Note
Data presented at the 53rd AEPC Meeting, May 15-18, 2019, Seville,
Spain.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to
the research, authorship, and/or publication of this article.
Funding
The author(s) received no financial support for the research, author-
ship, and/or publication of this article.
ORCID iDs
Alessia Callegari https://orcid.org/0000-0001-6043-655X
Daniel Quandt https://orcid.org/0000-0001-5199-0313
References
1. Kreutzer C, Kreutzer J, Kreutzer GO. Reflections on five decades
of the Fontan Kreutzer procedure. Front Pediatr. 2013;1:45.
2. Rodefeld MD, Bromberg BI, Schuessler RB, Boineau JP, Cox JL,
Huddleston CB. Atrial flutter after lateral tunnel construction in
the modified Fontan operation: a canine model. J Thorac Cardi-
ovasc Surg. 1996;111(3):514-526.
3. Tweddell JS, Nersesian M, Mussatto KA, et al. Fontan palliation
in the modern era: factors impacting mortality and morbidity. Ann
Thorac Surg. 2009;88(4):1291-1299.
4. Frescura C, Thiene G. The new concept of univentricular heart.
Front Pediatr. 2014;2:62.
5. Kirklin JK, Brown RN, Bryant AS, et al. Is the “perfect Fontan”
operation routinely achievable in the modern era? Cardiol Young.
2008;18(3):328-336.
6. de Leval MR, Deanfield JE. Four decades of Fontan palliation.
Nat Rev Cardiol. 2010;7(9):520-527.
7. Firdouse M, Agarwal A, Chan AK, Mondal T. Thrombosis and
thromboembolic complications in Fontan patients: a literature
review. Clin Appl Thromb Hemost. 2014;20(5):484-492.
8. Odegard KC, McGowan FX, Zurakowski D, et al. Coagulation
factor abnormalities in patients with single-ventricle physiology
immediately prior to the Fontan procedure. Ann Thorac Surg.
2002;73(6):1770-1777.
9. Odegard KC, McGowan FX, Zurakowski D, et al. Procoagulant
and anticoagulant factor abnormalities following the Fontan pro-
cedure: increased factor VIII may predispose to thrombosis.
J Thorac Cardiovasc Surg. 2003;125(6):1260-1267.
10. Odegard KC, McGowan FX, DiNardo JA, et al. Coagulation
abnormalities in patients with single-ventricle physiology precede
the Fontan procedure. J Thorac Cardiovasc Surg. 2002;123(3):
459-465.
11. Odegard KC, Zurakowski D, DiNardo JA, et al. Prospective long-
itudinal study of coagulation profiles in children with hypoplastic
left heart syndrome from stage I through Fontan completion.
J Thorac Cardiovasc Surg. 2009;137(4):934-941.
12. Binotto MA, Maeda NY, Lopes AA. Evidence of endothelial
dysfunction in patients with functionally univentricular physiol-
ogy before completion of the Fontan operation. Cardiol Young.
2005;15(1):26-30.
13. Jahangiri M, Shore D, Kakkar V, Lincoln C, Shinebourne E.
Coagulation factor abnormalities after the Fontan procedure
and its modifications. J Thorac Cardiovasc Surg. 1997;113(6):
989-992.
14. Cromme-Dijkhuis AH, Henkens CM, Bijleveld CM, Hillege HL,
Bom VJ, van der Meer J. Coagulation factor abnormalities as
possible thrombotic risk factors after Fontan operations. Lancet.
1990;336(8723):1087-1090.
15. Tomkiewicz-Pajak L, Hoffman P, Trojnarska O, Lipczyn´ska M,
Podolec P, Undas A. Abnormalities in blood coagulation, fibri-
nolysis, and platelet activation in adult patients after the Fontan
procedure. J Thorac Cardiovasc Surg. 2014;147(4):1284-1290.
16. Ravn HB, Hjortdal VE, Stenbog EV, et al. Increased platelet
reactivity and significant changes in coagulation markers after
cavopulmonary connection. Heart. 2001;85(1):61-65.
17. Makhija Z, Sharma R. Hematologic alterations in patients with
functionally univentricular hearts. World J Pediatr Congenit
Heart Surg. 2012;3(3):350-358.
18. Rask O, Hanse´us K, Ljung R, Strandberg K, Berntorp E. Lower
incidence of procoagulant abnormalities during follow-up after
Callegari et al 7
creation of the Fontan circulation in children. Cardiol Young.
2009;19(2):152-158.
19. Procelewska M, Kolcz J, Januszewska K, Mroczek T, Malec E.
Coagulation abnormalities and liver function after hemi-Fontan and
Fontan procedures—the importance of hemodynamics in the early
postoperative period.Eur JCardiothorac Surg. 2007;31(5):866-872.
20. Veldtman GR,Webb GD. Improved survival in Fontan-associated
protein-losing enteropathy. J Am Coll Cardiol. 2014;64(1):63-65.
21. Ozbek N, Atac¸ FB, Yildirim SV, et al. Analysis of prothrombotic
mutations and polymorphisms in children who developed throm-
bosis in the perioperative period of congenital cardiac surgery.
Cardiol Young. 2005;15(1):19-25.
22. Gurgey A, Ozyurek E, Gu¨mru¨k F, et al. Thrombosis in children
with cardiac pathology: frequency of factor V Leiden and pro-
thrombin G20210A mutations. Pediatr Cardiol. 2003;24(3):
244-248.
23. Toulon P, Berruyer M, Brionne-Franc¸ois M, et al. Age depen-
dency for coagulation parameters in paediatric populations.
Results of a multicentre study aimed at defining the age-
specific reference ranges. Thromb Haemost. 2016;116(1):9-16.
24. Georgekutty J, Kazerouninia A, Wang Y, et al. Novel oral antic-
oagulant use in adult Fontan patients: a single center experience.
Congenit Heart Dis. 2018;13(4):541-547.
25. Sluysmans T, Ovaert C, d’Udekem Y, Barrea C.
Coagulation factor abnormalities after the Fontan procedure
and its modifications. J Thorac Cardiovasc Surg. 1999;
117(5):1038.
26. Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor
of blood coagulation. Lancet. 1982;2(8296):463-467.
27. Ohuchi H, Yasuda K, Miyazaki A, et al. Prevalence and predictors
of haemostatic complications in 412 Fontan patients: their rela-
tion to anticoagulation and haemodynamics. Eur J Cardiothorac
Surg. 2015;47(3):511-519.
28. Ten VS, Pinsky DJ. Endothelial response to hypoxia: physiologic
adaptation and pathologic dysfunction. Curr Opin Crit Care.
2002;8(3):242-250.
29. Horigome H, Hiramatsu Y, Shigeta O, Nagasawa T, Matsui A.
Overproduction of platelet microparticles in cyanotic congenital
heart disease with polycythemia. J Am Coll Cardiol. 2002;39(6):
1072-1077.
8 Clinical and Applied Thrombosis/Hemostasis
